CARB-X IS FUNDING AUSTRALIAN-BIOTECH SPEEDX TO DEVELOP A RAPID POINT-OF-CARE DIAGNOSTIC FOR SEXUALLY TRANSMITTED DISEASES CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE
CARB-X is awarding SpeeDx, a diagnostics company in Sydney, Australia, up to $1.8 million to develop a rapid test for Chlamydia trachomatis and Neisseria gonorrhoeae, sexually transmitted bacteria that can cause serious infections and that are spreading around the world at alarming rates. SpeeDx is also eligible for $1.9 million in additional funds from CARB-X if the project achieves certain milestones, subject to available funds.
SpeeDx has developed a rapid, molecular test using polymerase chain reaction (PCR) technology called InSignia™, that is able to identify whether an active infection is associated with Chlamydia trachomatis or Neisseria gonorrhoeae.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.